Literature DB >> 15110512

Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone?

Yoshichika Arakawa, Yasuyoshi Ike, Mitsuaki Nagasawa.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15110512     DOI: 10.1016/S0140-6736(04)16068-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

2.  Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Authors:  Sarah W Satola; Monica M Farley; Karen F Anderson; Jean B Patel
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

Review 3.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

4.  A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).

Authors:  Andreas Voss; Johan W Mouton; Erika P van Elzakker; Ron G Hendrix; Wil Goessens; Jan A Kluytmans; Paul F Krabbe; Han J de Neeling; Jacobus H Sloos; Nefise Oztoprak; Robin A Howe; Timothy R Walsh
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-09-24       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.